



HAL
open science

Delay from treatment start to full effect of immunotherapies for multiple sclerosis

Izanne Roos, Emmanuelle Leray, Federico Frascoli, Romain Casey, J William L Brown, Dana Horakova, Eva Havrdova, Maria Trojano, Francesco Patti, Guillermo Izquierdo, et al.

► To cite this version:

Izanne Roos, Emmanuelle Leray, Federico Frascoli, Romain Casey, J William L Brown, et al.. Delay from treatment start to full effect of immunotherapies for multiple sclerosis. *Brain - A Journal of Neurology*, 2020, 143 (9), pp.2742-2756. 10.1093/brain/awaa231 . hal-02955197

HAL Id: hal-02955197

<https://ehesp.hal.science/hal-02955197v1>

Submitted on 23 Sep 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Title:

Determinants of therapeutic lag in multiple sclerosis

Corresponding Author:

Tomas Kalincik

CORe, Department of Medicine, University of Melbourne, 300 Grattan St,
Melbourne, 3050, Australia

tomas.kalincik@unimelb.edu.au

Izanne Roos; CORe, Department of Medicine, University of Melbourne, Melbourne,
Australia; Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia
Emmanuelle Leray; Univ Rennes / EHESP, REPERES (Pharmaco-epidemiology and
Health services research) - EA 7449, Rennes, France

Federico Frascoli; Faculty of Science, Engineering and Technology, School of
Science, Department of Mathematics, Swinburne University of Technology,
Melbourne, Australia

Romain Casey; Université de Lyon, Université Claude Bernard Lyon 1, F-69000
Lyon, France; Hospices Civils de Lyon, Service de Neurologie, sclérose en plaques,
pathologies de la myéline et neuro-inflammation, F-69677 Bron, France;
Observatoire Français de la Sclérose en Plaques, Centre de Recherche en
Neurosciences de Lyon, INSERM 1028 et CNRS UMR 5292, F-69003 Lyon, France;
EUGENE DEVIC EDMUS Foundation against multiple sclerosis, state-approved
foundation, F-69677 Bron, France.

J. William L. Brown; Department of Clinical Neurosciences, University of Cambridge,
Cambridge, United Kingdom

Dana Horakova; Department of Neurology and Center of Clinical Neuroscience, First
Faculty of Medicine, Charles University in Prague and General University Hospital,
Prague, Czech Republic

Eva Kubala Havrdova; Department of Neurology and Center of Clinical
Neuroscience, First Faculty of Medicine, Charles University in Prague and General
University Hospital, Prague, Czech Republic

Marc Debouverie; Centre hospitalier régional universitaire de Nancy, Hôpital central,
Service de neurologie, Nancy, France

Maria Trojano; Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari, Bari, Italy

Francesco Patti; GF Ingrassia Department, University of Catania, Catania, Italy; Policlinico G Rodolico

Guillermo Izquierdo; Hospital Universitario Virgen Macarena, Sevilla, Spain

Sara Eichau; Hospital Universitario Virgen Macarena, Sevilla, Spain

Gilles Edan; Centre hospitalier universitaire de Rennes, Hôpital Pontchaillou, Service de neurologie, Rennes, France

Alexandre Prat; CHUM MS Center and Université de Montreal, Montreal, Canada

Marc Girard; CHUM MS Center and Université de Montreal, Montreal, Canada

Pierre Duquette; CHUM MS Center and Université de Montreal, Montreal, Canada

Marco Onofri; Department of Neuroscience, Imaging, and Clinical Sciences, University G. d'Annunzio, Chieti, Italy

Alessandra Lugaresi; IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italia; Dipartimento di Scienze Biomediche e Neuromotorie, Università di Bologna, Bologna, Italia

Pierre Grammond; CISSS Chaudière-Appalache, Lévis, Canada

Jonathan Ciron; Centre hospitalier universitaire de Toulouse, Hôpital Purpan, Service de neurologie inflammatoire et neuro-oncologie, Toulouse, France;

Aurélie Ruet; Centre hospitalier universitaire de Bordeaux, Hôpital Pellegrin, Service de neurologie, Bordeaux, France;

Serkan Ozakbas; Dokuz Eylul University, Konak/Izmir, Turkey

Jérôme De Seze; Hôpitaux universitaires de Strasbourg, Hôpital de Hautepierre, Service des maladies inflammatoires du système nerveux – neurologie, Strasbourg, France;

Elisabeth Maillart; Assistance publique des hôpitaux de Paris, Hôpital de la Pitié-Salpêtrière, Service de neurologie, Paris, France;

Hélène Zephir; Centre hospitalier universitaire de Lille, Hôpital Salengro, Service de neurologie D, Lille, France;

Maria José Sá; Centro Hospitalar Universitário de São João and Universidade Fernando Pessoa, Porto, Portugal

Bruno Stankoff; Assistance publique des hôpitaux de Paris, Hôpital Saint-Antoine, Service de neurologie, Paris, France;

Patrizia Sola; Department of Neuroscience, Azienda Ospedaliera Universitaria, Modena, Italy

Diana Ferraro; Department of Biomedical, Metabolic and Neurosciences, University of Modena and Reggio Emilia, Modena, Italy

Pierre Labauge; Centre hospitalier universitaire de Montpellier, Hôpital Gui de Chauliac, Service de neurologie, Montpellier, France

Gilles Defer; Centre hospitalier universitaire de Caen Normandie, Service de neurologie, Hôpital Côte de Nacre, Caen, France

Roberto Bergamaschi; IRCCS Mondino Foundation, Pavia, Italy

Christine Lebrun-Frenay; Centre hospitalier universitaire de Nice, Université Nice Côte d'Azur, Hôpital Pasteur, Service de neurologie, Nice, France

Cavit Boz; KTU Medical Faculty Farabi Hospital, Trabzon, Turkey

Elisabetta Cartechini; UOC Neurologia, Azienda Sanitaria Unica Regionale Marche - AV3, Macerata, Italy

Thibault Moreau; Centre hospitalier universitaire Dijon Bourgogne, Hôpital François Mitterrand, Service de neurologie, maladies inflammatoires du système nerveux et neurologie générale, Dijon, France

David Laplaud; 1 CHU de Nantes, Service de Neurologie & CIC015 INSERM, F-44093 Nantes, France; 2 INSERM CR1064, F-44000 Nantes, France

Jeannette Lechner-Scott; School of Medicine and Public Health, University Newcastle, Newcastle, Australia; Department of Neurology, John Hunter Hospital, Hunter New England Health, Newcastle, Australia

Francois Grand'Maison; Neuro Rive-Sud, Quebec, Canada

Raymond Hupperts; Zuyderland Ziekenhuis, Sittard, Netherlands

Murat Terzi; Medical Faculty, 19 Mayıs University, Samsun, Turkey

Franco Granella; Department of Medicine and Surgery, University of Parma, Parma, Italy; Department of General Medicine, Parma University Hospital, Parma, Italy

Raed Alroughani; Division of Neurology, Department of Medicine, Amiri Hospital, Sharq, Kuwait

Gerardo Iuliano; Ospedali Riuniti di Salerno, Salerno, Italy

Vincent Van Pesch; Cliniques universitaires Saint-Luc, UCLouvain

Bart Van Wijmeersch; Rehabilitation and MS-Centre Overpelt and Hasselt University, Hasselt, Belgium

Daniele L.A Spitaleri; Neurological Unit AORN San G. Moscati, Avellino, Italy

Aysun Soysal; Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases, Istanbul, Turkey

Eric Berger; Centre hospitalier régional universitaire de Besançon, Hôpital Jean Minjoz, Service de neurologie, Besançon, France;

Julie Prevost; CSSS Saint-Jérôme, Saint-Jerome, Canada

Eduardo Aguera-Morales; Hospital Universitario Reina Sofia Cordoba (IMIBIC), Cordoba, Spain

Pamela McCombe; University of Queensland, Brisbane, Australia; Royal Brisbane and Women's Hospital

Javier Olascoaga; Instituto de Investigación Sanitaria Biodonostia, Hospital Universitario Donostia, San Sebastian, Spain

Pierre Clavelou; Centre hospitalier universitaire de Clermont-Ferrand, Hôpital Gabriel-Montpied, Service de neurologie, Clermont-Ferrand, France;

Jean Pelletier; Assistance publique des hôpitaux de Marseille, Centre hospitalier de la Timone, Service de neurologie et unité neuro-vasculaire, Marseille, France;

Recai Turkoglu; Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey

Bruno Stankoff; Assistance publique des hôpitaux de Paris, Hôpital Saint-Antoine, Service de neurologie, Paris, France

Olivier Gout; Fondation Adolphe de Rothschild de l'œil et du cerveau, Service de neurologie, Paris, France

Eric Thouvenot; Centre hospitalier universitaire de Nîmes, Hôpital Carémeau, Service de neurologie, Nîmes, France;

Olivier Heinzlef; Centre hospitalier intercommunal de Poissy Saint-Germain-en-Laye, Service de neurologie, Poissy, France;

Youssef Sidhom; Department of Neurology, Razi Hospital, Manouba, Tunisia

Riadh Gouider; Department of Neurology, Razi Hospital, Manouba, Tunisia

Tunde Csepany; Department of Neurology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary

Abullatif Al-Khedr; Centre hospitalier universitaire d'Amiens Picardie, Site sud, Service de neurologie, Amiens, France;

Bertrand Bourre; Centre hospitalier universitaire Rouen Normandie, Hôpital Charles-Nicolle, Service de neurologie, Rouen, France;

Olivier Casez; Centre hospitalier universitaire Grenoble-Alpes, Site nord, Service de neurologie, Grenoble/La Tronche, France;

Philippe Cabre; Centre hospitalier universitaire de Martinique, Hôpital Pierre Zobda-Quitman, Service de Neurologie, Fort-de-France, France;

Alexis Montcuquet; Centre hospitalier universitaire Limoges, Hôpital Dupuytren, Service de neurologie, Limoges, France;

Abir Wahab; Assistance publique des hôpitaux de Paris, Hôpital Henri Mondor, Service de neurologie, Créteil, France;

Jean-Philippe Camdessanche; Centre hospitalier universitaire de Saint-Étienne, Hôpital Nord, Service de neurologie, Saint-Étienne, France;

Aude Maurousset; Centre hospitalier régional universitaire de Tours, Hôpital Bretonneau, Service de neurologie, Tours, France;

Ivania Patry; Centre hospitalier sud francilien, Service de neurologie, Corbeil-Essonnes, France;

Karolina Hankiewicz; Centre hospitalier de Saint-Denis, Hôpital Casanova, Service de neurologie, Saint-Denis, France;

Corinne Pottier; Centre hospitalier de Pontoise, Service de neurologie, Pontoise, France;

Nicolas Maubeuge; Centre hospitalier universitaire de Poitiers, Site de la Milétrie, Service de neurologie, Poitiers, France;

Céline Labeyrie; Assistance publique des hôpitaux de Paris, Hôpital Bicêtre, Service de neurologie, Le Kremlin-Bicêtre, France;

Chantal Nifle; Centre hospitalier de Versailles, Hôpital André-Mignot, Service de neurologie, Le Chesnay, France;

Alasdair Coles; Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom

Charles B Malpas; CORe, Department of Medicine, University of Melbourne, Melbourne, Australia; Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia

Sandra Vukusic; Service de neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, 69677 Lyon/Bron, France; Centre des Neurosciences de Lyon, Observatoire Français de la Sclérose en Plaques, INSERM 1028 et CNRS UMR5292, 69003 Lyon, France; Université Claude Bernard Lyon 1, Faculté de médecine Lyon Est, F-69000 Lyon, France.

Helmut Butzkueven; Central Clinical School, Monash University, Melbourne, Australia; Department of Neurology, The Alfred Hospital, Melbourne, Australia; Department of Neurology, Box Hill Hospital, Monash University, Melbourne, Australia

Tomas Kalincik; CORe, Department of Medicine, University of Melbourne, Melbourne, Australia; Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia

On behalf of MSBase and OFSEP investigators

Word Count: 3100

ABSTRACT (250 words)

Objective: Explore the associations of patient and disease characteristics with the duration of therapeutic lag for relapses and disability progression.

Background: Therapeutic lag represents the delay from initiation of therapy to attainment of full treatment effect. Understanding the determinants of therapeutic lag provides valuable information for personalised choice of therapy in multiple sclerosis (MS).

Methods: Data from MSBase, a multinational MS registry, and OFSEP, the French MS registry, were used. Patients diagnosed with MS, minimum 1-year exposure to MS treatment, minimum 3-year pre-treatment follow up and yearly review were included in the analysis. We studied incidence of relapses and 6-month confirmed disability progression. Therapeutic lag was calculated by identifying the first local minimum of the first derivative after treatment start in subgroups stratified by patient and disease characteristics. Therapeutic lag under specific circumstances was then estimated in subgroups defined by combinations of individual clinical and demographic determinants.

Results: High baseline disability scores (EDSS), annualised relapse rate (ARR) ≥ 1 and male sex were associated with longer therapeutic lag on disability progression (T_d) in sufficiently populated groups: females with EDSS <6 and ARR <1 had mean T_d of 26.6 weeks (95%CI 18.2-34.9), males with EDSS <6 and ARR <1 31.0 weeks (95%CI 25.3-36.8), females with EDSS <6 and ARR ≥ 1 44.8 weeks (95%CI 24.5-65.1), and females with EDSS ≥ 6 , ARR <1 54.3 weeks (95%CI 47.2-61.5).

Conclusions: We have utilised a novel method for the quantification of clinical therapeutic lag in different patient groups. EDSS and ARR at the commencement of an MS therapy are the most important determinants of therapeutic lag.

INTRODUCTION

The goal of treatment in multiple sclerosis (MS) is prevention of long-term disability. After starting a disease modifying therapy (DMT), there is however a delay to full clinically apparent treatment effect, referred to as 'therapeutic lag'.¹ As treatment decisions are often made in the face of ongoing disease activity, accurate expectations of timing of treatment effect is clinically relevant.² Using an objective, differential calculus-derived method, the duration of therapeutic lag has recently been estimated to range between 12-30 weeks for relapses and 30-70 weeks for disability progression.(Roos et al. under review) Moreover, normalisation of brain atrophy rates (a marker of neuroaxonal loss) have been delayed up to 3 years after the commencement of natalizumab.³

It has been suggested that the duration of therapeutic lag is not uniform amongst patients, and may increase proportionate to the degree of pre-existing disability.⁴ A randomised placebo-controlled trial of interferon beta-1b in primary progressive MS failed to detect a beneficial treatment response after 2 years.⁵ However, when patient outcomes were revisited at year 7, after a 5-year treatment free period, cognitive and upper limb outcomes in patients initially randomised to interferon beta-1b were superior to those randomised to placebo.⁶ This suggests that in patients with progressive MS, therapeutic lag may obscure a detectable effect of therapy if not accounted for analytically. As yet, therapeutic lag has not been incorporated into clinical trial design. Understanding the effect of individual disease characteristics on the duration of therapeutic lag might aid personalised DMT decision-making.

In this study, we apply an objective, externally validated method to measure the duration of therapeutic lag with respect to disability progression and relapses. We aim to explore the associations of the duration of therapeutic lag with patient and disease characteristics.

METHODS

Ethics statement

The MSBase registry⁷ (registered with WHO ICTRP, ID ACTRN12605000455662) was approved by the Melbourne Health Human Research Ethics Committee, and by the local ethics committees in all participating centres (or exemptions granted, according to applicable local laws and regulations). Written informed consent was obtained from enrolled patients as required. The Observatoire Français de la Sclérose en Plaques (OFSEP) cohort⁸ (registered with WHO ICTRP, ID NCT02889965) was collected with approval from and in accordance with French *Commission Nationale Informatique et Libertés* and French law relative to observational research.

Population and data collection

Longitudinal clinical and demographic data were extracted from the MSBase registry (125 centres in 37 countries) and OFSEP registry (39 French centres) in December 2018. Inclusion criteria for this study consisted of: diagnosis of MS as per the 2005⁹ or 2010¹⁰ McDonald Criteria, commencement of and persistence on a DMT for at least 12 months, minimum 3-year pre-treatment follow up, yearly visits during the treatment epoch (defined below) and availability of the minimum dataset. The minimum dataset consisted of patient age, sex (dichotomised as male and female), disease phenotype, disability (quantified by the Expanded Disability Status Scale (EDSS)) at baseline and two subsequent timepoints at least 6 months apart, MS duration, relapses recorded during the follow up period, and date of treatment start and cessation (where applicable).

The prospective follow up period was defined as time from first to the last available EDSS. Study baseline was defined as the start of the index DMT. All DMTs were eligible for study inclusion. A treatment epoch was defined as time including three years prior to baseline and one year (for the effect of relapses) and three years (for the effect on disability; see below) after baseline. In patients in whom multiple eligible baselines were identified, multiple eligible treatment epochs per patient were studied. Each treatment epoch was treated as independent.

All data were prospectively collected during routine clinical care predominantly from tertiary multiple sclerosis centres and entered near real-time (at the time of a clinic visit) into the iMed patient record or online data entry system for MSBase or EDMUS patient record for OFSEP. Standardised data quality processes were applied as previously described.¹¹

Study outcomes

This study evaluated the time from treatment start to its full clinically manifest effect ('therapeutic lag') on disability progression and relapses in subgroups of patients with MS.

Disability progression was defined as an EDSS score increase of 1 point (1.5 points where EDSS is 0, 0.5 points if EDSS \geq 6), confirmed over \geq 6 months (in the absence of a relapse in the 30 days prior to confirmation), and sustained for the remainder of the treatment epoch.¹² Relapses were defined as new symptoms or exacerbation of existing symptoms for at least 24 hours, in the absence of a concurrent illness or fever, and occurring at least 30 days after a previous relapse.¹³

The first episode of demyelination was considered a relapse. For analysis of disability outcomes, patients were treated for at least one year, and all disability progression events recorded during a 3-year period were analysed, irrespective of treatment status. For the analysis of relapses patients required one year on-treatment follow up, and relapses recorded during this year were included in the analysis. Differences in analytical approaches are motivated by observations that the effect of DMTs on relapses is more immediate than the effect on disability (Roos et al).

Classification of MS phenotype was analysed as documented by the treating physician. Additionally, secondary progressive MS (SPMS) was analysed as defined by an objective algorithm, which identifies SPMS with 87% accuracy in a timely manner.¹⁴ Annualised relapse rate (ARR) was calculated as the annualized number of recorded relapses in the three years before baseline. MS duration and onset were calculated from the first MS symptom.

By separately plotting the incidence of relapses and disability progression events in subgroups stratified by patient and disease characteristics, the duration of therapeutic lag was calculated by identifying the first local minimum of the first derivative after treatment start (Roos et al.). This local minimum represents the timepoint at which stabilisation of the effect of treatment is reached on disability progression (T_d) and relapses (T_r). Estimates of therapeutic lag were recalculated by non-parametric bootstrap with 10,000 repetitions, without replacement.

Statistical analysis

Statistical analysis was conducted by IR using *R* (version 3.5.3). Point and interval estimates of distribution were expressed as means with 95% confidence intervals, or medians with quartiles, as appropriate.

Therapeutic lag (T_d and T_r) was calculated for patient subgroups stratified by their demographic and clinical characteristics. As discussed elsewhere (Roos et al.), a critical number of events are required to identify a stable, reliable estimate of therapeutic lag. Therefore, we only considered results from subgroups in whom more than 300 events were recorded (disability progression events or relapses), and for which T_d or T_r was identified in more than 80% of the bootstrap repetitions. Categorisation of continuous variables was performed by first computing quantiles and then aggregating the overlapping quantiles (Supplementary Table 1).

Studied potential baseline determinants of therapeutic lag were selected based on the results of prior studies^{1 4 15-17}: sex, age at start of index DMT, age at MS onset, ARR, MS duration, EDSS, pyramidal score, presence/absence of 6-month confirmed disability progression in the 3 years before baseline, slope of the disability trajectory (the regression line projected over the EDSS/time points), treatment with MS-specific DMT in the 6 months before baseline and reason for discontinuation of preceding DMT (as reported by the treating neurologist) if applicable. A prior analysis explored therapeutic lag in different DMTs: time to treatment effect for disability progression ranged between 30-52 weeks for all included therapies apart from interferon beta-1a IM (mean 70.4, 95% confidence interval [95%CI] 59.8-81.0) and time to treatment

effect for relapses ranged between 9.4-19.8 weeks for all included therapies apart from dimethyl fumarate (mean 30.2, 95%CI 26.6-33.7).(Roos et al.) Therefore, treatment identity was not considered to be a confounder of the estimated therapeutic lag and its effect on therapeutic lag was not evaluated in this study, unless dimethyl fumarate or interferon beta-1a IM were over-represented in any studied subgroup. In this circumstance the analysis was repeated after the exclusion of dimethyl fumarate (relapses) or interferon beta-1a (disability progression) treatment epochs.

Second, the patient characteristics identified by the above analysis as relevant determinants of T_d and T_r were included in pairwise analyses, in which therapeutic lag was estimated in groups defined by combinations of two characteristics. Third, combinations of determinants that consistently drove differences in therapeutic lag duration in the pairwise analyses were included in the final set of analyses in which groups were defined by combinations of multiple relevant patient characteristics. As mentioned above, we only considered results from sufficiently represented subgroups.

RESULTS

Patients and follow-up

A total of 5,415 patients (3,473 MSBase, 1,492 OFSEP) were included in the analysis of determinants of therapeutic lag for disability progression and 10,192 patients (6,051 MSBase, 4,141 OFSEP) in the determinants for relapses (figure 1). Characteristics of the study population are shown in Table 1 and the number of patients per contributing centre in Supplementary Table 2.

In the disability progression cohort, the index therapy was continued for a median duration of 3.6 years (2.4-5.3). Although population characteristics were largely similar between registries, more patients in MSBase were commenced on an injectable therapy at baseline than those in OFSEP (disability cohort: MSBase 51.7%, OFSEP 41.4%; relapse cohort: MSBase 44.6%, OFSEP 33.1%). In both

registries, the most common preceding DMT was an injectable therapy. Lack of efficacy was the most commonly reported reason for discontinuation of the preceding DMT. Details of the index DMT for each of the studied determinants of therapeutic lag are shown in Supplementary Table 3.

Table 1: Characteristics of the study population

Source	Disability Progression Cohort			Relapse Cohort		
	Overall <i>n</i> = 5415	MSBase <i>n</i> = 3473	OFSEP <i>n</i> = 1492	Overall <i>n</i> = 10192	MSBase <i>n</i> = 6051	OFSEP <i>n</i> = 4141
Female, <i>n</i> (%)	4142 (76)	2570 (74)	1134 (76)	7583 (74)	4478 (74)	3105 (75)
Treatment epochs, <i>n</i>	6551	4304	2247	12553	7606	4947
Age of MS onset, years ^a	27.9 (8.6)	27.8 (8.6)	28.2 (8.5)	28.4 (8.7)	28.2 (8.7)	28.6 (8.7)
Age at start of index DMT, years ^a	40.0 (9.5)	39.7 (9.4)	40.7 (9.7)	40.8 (9.7)	40.3 (9.6)	41.5 (9.9)
Disease duration, years ^b	10.6 [6.9, 15.7]	10.5 [6.7, 15.4]	10.9 [7.1, 16.1]	10.8 [6.9, 16.1]	10.5 [6.7, 15.7]	11.2 [7.4, 16.6]
Disability, EDSS step ^b	3.0 [2.0, 4.5]	3.0 [2.0, 4.0]	3.5 [2.0, 4.5]	3.0 [1.5, 4.0]	2.5 [1.5, 4.0]	3.0 [2.0, 4.5]
Pyramidal score, step ^a	1.8 (1.2)	1.8 (1.2)	1.6 (1.3)	1.7 (1.2)	1.8 (1.2)	1.6 (1.2)
Annualised relapse rate ^b	0.7 [0.3, 1.0]	0.7 [0.3, 1.0]	0.7 [0.3, 1.0]	0.3 [0.0, 1.0]	0.3 [0.3, 1.0]	0.3 [0.0, 1.0]
Disease course (%)						
Clinically isolated syndrome	82 (1.3)	43 (1.0)	39 (1.7)	195 (1.6)	85 (1.1)	110 (2.2)
Relapsing-remitting	5646 (86.2)	3780 (87.8)	1866 (83.0)	10819 (86.2)	6715 (88.3)	4104 (83.0)
Secondary progressive	745 (11.4)	419 (9.7)	326 (14.5)	1378 (11.0)	691 (9.1)	687 (13.9)
Primary progressive	78 (1.2)	62 (1.5)	16 (0.7)	161 (1.3)	115 (1.5)	46 (0.9)
DMT started at baseline (%)						
Injectable therapies	3159 (48.2)	2228 (51.7)	931 (41.4)	5030 (40.1)	3393 (44.6)	1637 (33.1)
Oral therapies	1747 (26.7)	1130 (32.5)	617 (27.5)	4677 (37.3)	2718 (35.7)	1959 (39.6)
Infusion therapies	1645 (25.1)	946 (22.0)	699 (31.1)	2846 (20.0)	1495 (24.7)	1351 (27.3)
DMT in 6 months preceding baseline (%)						
None	1507 (23.0)	955 (22.2)	552 (24.6)	2753 (21.9)	1630 (21.4)	1123 (22.7)
Injectable therapies	3914 (59.7)	2640 (61.3)	1274 (56.7)	7107 (56.6)	4578 (60.2)	2529 (51.2)
Infusion therapies	878 (13.4)	514 (11.9)	364 (16.2)	1695 (13.5)	839 (13.9)	856 (20.7)

Oral therapies	252 (3.9)	195 (4.5)	57 (2.5)	998 (8.0)	559 (7.3)	439 (10.6)
Reason for discontinuation of preceding DMT (%)						
No Preceding Treatment	1507 (23.0)	955 (22.2)	552 (24.6)	2753 (21.9)	1630 (21.4)	1123 (22.7)
Convenience	231 (3.5)	131 (3.0)	100 (4.5)	564 (4.5)	275 (3.6)	289 (5.8)
Lack of efficacy	1680 (25.6)	1042 (24.2)	638 (28.4)	3014 (24.0)	1710 (22.5)	1304 (26.4)
Lack of tolerance	882 (13.5)	455 (10.6)	427 (19.0)	1805 (14.4)	873 (11.5)	932 (18.8)
Pregnancy (including planned)	82 (1.3)	51 (1.2)	31 (1.4)	185 (1.5)	100 (1.3)	85 (1.7)
Scheduled stop	589 (9.0)	292 (6.8)	297 (13.2)	1213 (9.7)	547 (7.2)	666 (13.5)
Other	47 (0.7)	10 (0.2)	37 (1.6)	142 (1.1)	36 (0.5)	106 (2.1)
Reason not available	1533 (23.4)	1368 (31.8)	165 (7.3)	2877 (22.9)	2435 (32.0)	442 (8.9)
^a Mean (standard deviation)	^b Median [quartiles]					

DMT = disease modifying therapy; MS = multiple sclerosis

Injectable therapies: glatiramer acetate, interferon beta-1b IM, interferon beta-1b SC, interferon beta-1b

Oral therapies: fingolimod, dimethyl fumarate, teriflunomide, cladribine

Infusion therapies: natalizumab, ocrelizumab, alemtuzumab, rituximab, mitoxantrone

Clinically isolated syndrome: patients classified as clinically isolated syndrome at the start of their treatment, with ≥ 3 year follow up from their first symptoms.

Patient disposition is summarised per treatment epoch at the start of treatment. In patients with multiple eligible treatments, multiple epochs were studied.

Therapeutic lag for disability progression

We have identified three potential determinants of the duration of therapeutic lag for disability progression: disability (EDSS<6, 17.2 weeks, 13.6-20.5 [mean, 95% confidence interval]; EDSS≥6, 47.5, 23.7-71.3), relapse frequency (ARR<1, 29.2, 21.1-37.2; ARR≥1, 52.4, 38.9-65.9) and sex (female, 31.8, 26.2-37.5; male 55.8, 45.6-66.0) (figure 2). Patient and disease characteristics which did not influence T_d are shown in supplementary figure 1. Interferon beta-1a IM was not markedly over- or under-represented in any patient groups (supplementary table 3a) and therefore DMT choice at baseline was not included among the examined potential determinants of T_d . All three individual determinants (EDSS, ARR and sex) contributed to differences in T_d when combined in pairwise analyses (supplementary table 4) and were then included in the final set of analyses exploring all combinations of the three determinants. In these final models, T_d was successfully calculated in 4 groups in whom the number of disability progression events was sufficient, ≥300 (figure 3). In females with ARR<1 and EDSS<6 the mean T_d was 26.6 weeks (95%CI 18.2-34.9). This was 27.7 weeks shorter than the mean T_d among females with ARR<1 and EDSS≥6 (54.3, 95%CI 47.2-61.5), and not substantially different from males with ARR<1 and EDSS<6 (31.0, 95%CI 25.3-36.8). In females with ARR≥1 and EDSS<6, mean T_d was 44.8 weeks (24.5-65.1).

Therapeutic lag for relapses

Baseline EDSS (EDSS<2, 9.2 weeks, 7.0-11.4 [mean, 95% confidence interval]; EDSS≥2 and <6, 12.1, 11.1-13.2; EDSS ≥6, 16.9, 13.8-19.9), ARR (ARR<2, 14.9, 13.4-16.4; ARR≥2, 11.1, 9.3-12.8), sex (female, 14.3, 12.7-15.9; male, 9.8, 7.2-12.4), physician-defined MS phenotype (physician RRMS: 9.6, 7.5-11.6; physician SPMS: 14.7, 10.8-18.6) and algorithm-defined MS phenotype (algorithm RRMS: 10.0, 8.0-12.0; algorithm SPMS: 14.8, 11.8-17.7) were identified as potential determinants of T_r (figure 4); determinants which did not influence T_r are shown in supplementary figure 2. T_r was estimated in patients with RRMS and SPMS but not in patients with CIS or PPMS due to low total number of relapses (195 and 192 respectively). As T_r estimates for the algorithm-defined MS phenotype showed less overlap than for physician-defined MS phenotype, the former were used in

subsequent analyses. Dimethyl fumarate was neither markedly over- nor under-represented in any patient groups (supplementary table 3b) and therefore index DMT was not included in the estimation of T_r . Pairwise analyses of the individual determinants suggested that baseline EDSS, ARR and MS phenotype were independently associated with T_r (supplementary table 5) and were included in the set of analyses exploring all combinations of the four determinants. In these final models, T_r was calculated in 7 groups in whom the number of relapses was ≥ 300 (figure 5). Most notably, T_r was shorter in patients with RRMS and an EDSS <6 compared to the other represented groups. In patients with RRMS and an ARR <2 , T_r was approximately 5 weeks shorter in patients with an EDSS <6 compared to ≥ 6 . Detailed estimates of T_r in patient groups are shown in figure 5.

DISCUSSION

This study from the two largest MS registries, MSBase and OFSEP, showed that the time from commencing MS immunotherapy to its full clinically manifest effect (here termed therapeutic lag) is prolonged especially in patients with greater disability. Other contributing factors include low relapse frequency prior to commencement of therapy (associated with shorter therapeutic lag for disability progression events ~~but longer lag to maximum effect on relapses~~) and sex (with a mildly shorter time to maximum treatment effect on disability progression among females). Therapeutic lag for relapses was mildly prolonged in SPMS.

In contrast with evidence that DMTs reduce long term disability progression in RRMS, results in progressive MS have been comparatively disappointing. Beyond the pathologic differences in each disease stage, proposed methodological reasons have included patient selection, outcome selection, clinical trial design and therapeutic lag. Therapeutic lag was anecdotally observed when differences in disability outcomes occurred at year 7, but not year 2, of a randomised double-blind placebo-controlled trial of interferon beta-1b in PPMS.⁶ Our results show that T_r and T_d increase with baseline EDSS. Similarly, a post-hoc analysis of the SPECTRIMS (interferon beta-1a in SPMS)¹⁸ and PROMISE (interferon beta-1a in PPMS)¹⁹ trials reported that treatments influenced disability progression with a 2-2.5-year delay and that therapeutic lag duration increased with baseline EDSS.⁴ Whilst these findings

mirror our own, there were important differences in the methodology used to estimate lag duration. Whereas the post-hoc analysis of the two clinical trials approximated the duration of *therapeutic lag (years) = baseline EDSS - 3 years*, we used an objective method based on differential calculus, suitable for calculation of therapeutic lag in sufficiently large subgroups, which we have validated in 2 non-overlapping registries (Roos et al., 2020, manuscript under review).

Treatments in MS predominantly act by modifying the inflammatory processes, to which the loss of nervous tissue is secondary.²⁰ Therefore, prevention of further axonal damage, through the immunosuppressive/immunomodulatory action of DMTs occurs by definition with a delay. There are a number of factors that can define a duration of such delay. For instance, the influence of EDSS on therapeutic lag is consistent with the hypothesis that the CNS possesses a degree of functional reserve capacity that can mask the true extent of axonal loss early in MS.¹ Functional reserve reduces with increasing EDSS as illustrated by incomplete relapse recovery in subjects with an EDSS ≥ 3 .¹⁷ In cases with higher EDSS, when the reserve has been exhausted, it is suggested that any therapeutic effects would only become apparent once the degeneration of already damaged and vulnerable axons is complete.¹ This manifests as therapeutic lag.

The role of MS phenotype in therapeutic lag was explored using both physician- and algorithm-defined definitions of SPMS; both definitions of MS phenotype led to similar estimates of lag. In the “multivariable” model that accounted for interactions among the individual determinants of T_r , the addition of MS phenotype contributed only minimally to the differences in the duration of T_r within the sufficiently populated groups - i.e. T_r was only 5 weeks longer in secondary progressive compared to relapsing-remitting patients with EDSS 2-6 and ARR ≤ 2 . MS phenotype did not significantly contribute to the duration of T_d . The observation that therapeutic lag duration was influenced by EDSS more consistently than MS phenotype supports the hypothesis that MS is a continuum, with elements of neuroaxonal loss and progression throughout its disease course, rather than a disease consisting of clearly separable phases.²¹⁻²⁴

Whereas one prior study¹⁵ showed no difference in the time to the effect of natalizumab on relapses between patients with and without highly active MS (≥ 2 relapses in the year before baseline), ARR was a significant modifier of therapeutic lag for both disability progression and relapses in our analysis. Patients with $ARR \geq 2$ had a mean 4-week shorter T_r than those with $ARR < 2$. Considering the anti-inflammatory and immunomodulatory mechanisms of current DMTs for MS, it is not unexpected that they show more pronounced, and earlier, effect on the absolute drop in relapse incidence in patients with higher pre-treatment ARR - a clinical presentation of episodic, therapeutically modifiable inflammatory activity.¹⁶ Conversely, our observation that higher pre-treatment ARR prolongs therapeutic lag for disability progression is consistent with previous research that showed a positive association between high ARR and worse disability outcomes in MS.^{25 26} Therefore, lowering of relapse activity below the critical level to enable stabilisation of (or recovery from) disability is expected to be prolonged among patients in whom the pre-treatment level of relapse activity was high.

Whilst male sex is associated with faster disability accrual^{12 27-30}, the role of sex in therapeutic lag has not previously been explored. Male sex was weakly associated with longer T_d , but sex was not found to consistently drive differences in T_r .

Studies of observational data are subject to a number of potential limitations and biases. Variable data quality was controlled through the use of a validated data quality control process.¹¹ Selection and reporting bias was addressed through the inclusion of two largely non-overlapping data sources from predominantly academic MS centres (MSBase, a global registry, and OFSEP, a national cohort) with near-real time data acquisition and prospectively defined observational plans. T_d and T_r was only estimated for subgroups in which more than 300 relapses or progression events occurred as the underlying method is dependent on a critical mass of events to consistently identify the first local minimum of the first derivative of relapse incidence (Roos et al., 2020, under review). Where an insufficient number of events were present analyses were discontinued. There are therefore groups of determinants, particularly in the assessment of T_d in groups defined by multiple interacting patient characteristics, for which therapeutic lag could not be calculated. In an effort to maximise analytical power, we have combined data from the two largest MS

registries. It is also reassuring that the sufficiently powered groups included in the analysis represent the most common clinical scenarios encountered in practice. Because the method requires that therapeutic lag is estimated within discrete groups, we have categorised continuous determinants. While this may lead to some loss of information, we have ensured that the groups defined on categorised variables are internally consistent with regards to the duration of therapeutic lag.

DMT as a determinant of therapeutic lag was explored in a previous analysis (Roos et al. 2020, under review). Whilst T_r and T_d did not differ between most therapies, therapeutic lag tended to be relatively prolonged in dimethyl fumarate (T_r) and interferon beta-1a IM (T_d). Neither of these therapies were represented disproportionately within any of the groups defined by relevant determinants of therapeutic lag, and were therefore unlikely to obscure or inflate the observed therapeutic lag.

As this study did not include patients treated within 3 years of MS onset, or patients treated for less than 1 year, our conclusions cannot be generalised to these patient groups. Reassuringly, neither MS duration nor the reported reason for discontinuation of the preceding DMT were found to influence T_r or T_d . In addition, too few patients with PPMS or CIS were included to explore the duration of therapeutic lag in these MS phenotypes; our conclusions can therefore not be extended to these groups.

The EDSS has a number of limitations as a marker of disability progression³¹; we have utilised this disability scale due to its widespread use and availability in registry data, enabling combining information from two separate registries. We have aimed at improving intra- and inter-rater reliability by using specialist neurologist EDSS raters³² and a robust definition of disability progression.¹² Only clinical markers of therapeutic lag have been studied in this analysis as observational data, with semiquantitative imaging information acquired at varying intervals, is not suited to assess the radiological onset of treatment effect.

MS is a heterogenous disease, and it is highly desirable to personalise treatment based on patients' individual characteristics - demographic and clinical.³³ In the present study, we identified disability and relapse activity immediately prior to commencing a new MS immunotherapy as factors that most consistently influence the duration of therapeutic lag for disability progression and relapses. Sex has

additional influence on the lag of the effect of therapy on disability progression, and MS phenotype contributes to the duration of therapeutic lag with regards to relapses. This knowledge will contribute to the therapeutic decisions in response to reactivation of MS early after patients commenced a new immunotherapy. It is also of relevance to future reanalysis of clinical trials in patients with more advanced disease and design of future clinical trials in progressive MS. Treatment outcomes in cohorts enriched with patients with higher disability scores and relapse activity should be interpreted with the expected duration of therapeutic lag in sight.

ACKNOWLEDGEMENTS

We wish to thank all patients and their carers who have participated in this study and who have contributed data to the MSBase and OFSEP cohorts. Contributing members of OFSEP and the MSBase Study Group is given in the online supplement.

COMPETING INTERESTS

The authors have received research support, support to attend conferences, speaker honoraria and fees for participation at advisory boards from Actelion, Almirall, Bayer-Schering, Biogen, BioCSL, Celgene, EMD, Geneuro, Medday, Merck, Myalin, Novartis, Roche, Sanofi-Genzyme, Teva, WebMD Global outside the submitted work.

FUNDING

This study was supported by the EDMUS Foundation and NHMRC [1140766, 1129189, 1157717]. IR is supported by a MSIF-ARSEP McDonald fellowship grant and a Melbourne Research Scholarship. The MSBase Foundation is a not-for-profit organization that receives support from Biogen, Novartis, Merck, Roche, Teva and Sanofi Genzyme. The study was conducted separately and apart from the guidance of the sponsors. The Observatoire Français de la Sclérose en Plaques (OFSEP) is supported by a grant provided by the French State and handled by the "Agence Nationale de la Recherche," within the framework of the "Investments for the Future" program, under the reference ANR-10-COHO-002, by the Eugène Devic EDMUS Foundation against multiple sclerosis and by the ARSEP Foundation.

DATA AVAILABILITY STATEMENT

MSBase is a data processor, and warehouses data from individual principal investigators who agree to share their datasets on a project-by-project basis. Data access to external parties can be granted upon reasonable request at the sole discretion of each OFSEP and MSBase Principal Investigator (the data controllers), who will need to be approached individually for permission.

REFERENCES

1. Giovannoni G, Cutter G, Sormani MP, et al. Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses. *Mult Scler Relat Disord* 2017;12:70-78. doi: 10.1016/j.msard.2017.01.007 [published Online First: 2017/03/12]
2. Montalban X, Gold R, Thompson AJ, et al.ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. *Mult Scler* 2018;24(2):96-120. doi: 10.1177/1352458517751049 [published Online First: 2018/01/23]
3. Sastre-Garriga J, Tur C, Pareto D, et al. Brain atrophy in natalizumab-treated patients: A 3-year follow-up. *Mult Scler* 2015;21(6):749-56. doi: 10.1177/1352458514556300 [published Online First: 2014/11/14]
4. Sormani MP, Giovannoni G. Therapeutic lag: is treatment effect delayed in progressive MS? *Multiple Sclerosis Journal* 2016;22(3_suppl):7-87. doi: 10.1177/1352458516663068
5. Montalban X, Sastre-Garriga J, Tintore M, et al. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. *Mult Scler* 2009;15(10):1195-205. doi: 10.1177/1352458509106937 [published Online First: 2009/10/03]
6. Tur C, Montalban X, Tintore M, et al. Interferon beta-1b for the treatment of primary progressive multiple sclerosis: five-year clinical trial follow-up. *Arch Neurol* 2011;68(11):1421-7. doi: 10.1001/archneurol.2011.241 [published Online First: 2011/11/16]
7. Butzkueven H, Chapman J, Cristiano E, et al. MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis. *Mult Scler* 2006;12(6):769-74. doi: 10.1177/1352458506070775 [published Online First: 2007/02/01]

8. Vukusic S, Casey R, Rollot F, et al. Observatoire Francais de la Sclerose en Plaques (OFSEP): A unique multimodal nationwide MS registry in France. *Mult Scler* 2018;1352458518815602. doi: 10.1177/1352458518815602 [published Online First: 2018/12/14]
9. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". *Ann Neurol* 2005;58(6):840-6. doi: 10.1002/ana.20703 [published Online First: 2005/11/12]
10. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. *Annals of Neurology* 2011;69(2):292-302. doi: 10.1002/ana.22366
11. Kalincik T, Kuhle J, Pucci E, et al. Data quality evaluation for observational multiple sclerosis registries. *Multiple Sclerosis Journal* 2017;23(5):647-55. doi: 10.1177/1352458516662728 [published Online First: 2016/08/03]
12. Kalincik T, Cutter G, Spelman T, et al. Defining reliable disability outcomes in multiple sclerosis. *Brain* 2015;138(11):3287-98. doi: 10.1093/brain/awv258
13. Schumacher GA, Beebe G, Kibler RF, et al. Problems of Experimental Trials of Therapy in Multiple Sclerosis: Report by the Panel on the Evaluation of Experimental Trials of Therapy in Multiple Sclerosis. *Ann N Y Acad Sci* 1965;122(1):552-68. doi: doi:10.1111/j.1749-6632.1965.tb20235.x [published Online First: 1965/03/31]
14. Lorscheider J, Buzzard K, Jokubaitis V, et al. Defining secondary progressive multiple sclerosis. *Brain* 2016;139(Pt 9):2395-405. doi: 10.1093/brain/aww173 [published Online First: 2016/07/13]
15. Kappos L, O'Connor PW, Polman CH, et al. Clinical effects of natalizumab on multiple sclerosis appear early in treatment course. *J Neurol* 2013;260(5):1388-95. doi: 10.1007/s00415-012-6809-7 [published Online First: 2013/01/08]
16. Hutchinson M, Kappos L, Calabresi PA, et al. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. *J Neurol* 2009;256(3):405-15. doi: 10.1007/s00415-009-0093-1 [published Online First: 2009/03/25]
17. Lublin FD, Cutter G, Giovannoni G, et al. Natalizumab reduces relapse clinical severity and improves relapse recovery in MS. *Mult Scler Relat Disord*


2014;3(6):705-11. doi: 10.1016/j.msard.2014.08.005 [published Online First: 2015/04/22]

18. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in M. S. Study Group. Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results. *Neurology* 2001;56(11):1496-504. doi: 10.1212/wnl.56.11.1496 [published Online First: 2001/06/13]
19. Wolinsky JS, Narayana PA, O'Connor P, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. *Ann Neurol* 2007;61(1):14-24. doi: 10.1002/ana.21079 [published Online First: 2007/01/31]
20. Lassmann H. Targets of therapy in progressive MS. *Mult Scler* 2017;23(12):1593-99. doi: 10.1177/1352458517729455 [published Online First: 2017/10/19]
21. Kantarci OH, Lebrun C, Siva A, et al. Primary Progressive Multiple Sclerosis Evolving From Radiologically Isolated Syndrome. *Ann Neurol* 2016;79(2):288-94. doi: 10.1002/ana.24564 [published Online First: 2015/11/26]
22. Kappos L, Butzkueven H, Wiendl H, et al. Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study. *Mult Scler* 2018;24(7):963-73. doi: 10.1177/1352458517709619 [published Online First: 2017/05/31]
23. Lorscheider J, Benkert P, Schädelin S, et al.ECTRIMS 2019 - Oral Presentation: Disability progression unrelated to relapses in relapsing-remitting multiple sclerosis: insights from the Swiss multiple sclerosis cohort study. *Multiple Sclerosis Journal* 2019;25(2_suppl):3-130. doi: 10.1177/1352458519868070
24. Lizak N, Lugesesi A, Alroughani R, et al. Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. *J Neurol Neurosurg Ps* 2017;88(3):196-203. doi: 10.1136/jnnp-2016-313976 [published Online First: 2016/09/30]
25. Jokubaitis VG, Spelman T, Kalincik T, et al. Predictors of long-term disability accrual in relapse-onset multiple sclerosis. *Ann Neurol* 2016;80(1):89-100. doi: 10.1002/ana.24682 [published Online First: 2016/05/05]
26. Lublin FD, Baier ML, Cutter GR. Effect of relapses on development of residual deficit in multiple sclerosis. *American Academy of Neurology* 2003;61(11):1528-32.

27. Leray E, Yaouanq J, Le Page E, et al. Evidence for a two-stage disability progression in multiple sclerosis. *Brain* 2010;133(Pt 7):1900-13. doi: 10.1093/brain/awq076 [published Online First: 2010/04/29]
28. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. *Brain* 2003;126(Pt 4):770-82. [published Online First: 2003/03/05]
29. Kalincik T, Vivek V, Jokubaitis V, et al. Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. *Brain* 2013;136(Pt 12):3609-17. doi: 10.1093/brain/awt281 [published Online First: 2013/10/22]
30. Ribbons KA, McElduff P, Boz C, et al. Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS. *PLoS One* 2015;10(6):e0122686. doi: 10.1371/journal.pone.0122686 [published Online First: 2015/06/06]
31. Hobart J, Freeman J, Thompson A. Kurtzke scales revisited: the application of psychometric methods to clinical intuition. *Brain* 2000;123 (Pt 5):1027-40. doi: 10.1093/brain/123.5.1027 [published Online First: 2000/04/25]
32. D'Souza M, Yaldizli O, John R, et al. Neurostatus e-Scoring improves consistency of Expanded Disability Status Scale assessments: A proof of concept study. *Mult Scler* 2017;23(4):597-603. doi: 10.1177/1352458516657439 [published Online First: 2016/07/02]
33. Rotstein D, Montalban X. Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. *Nature Reviews Neurology* 2019;15(5):287-300. doi: 10.1038/s41582-019-0170-8

FIGURE LEGENDS

Figure 1: CONSORT Diagram



*Patients excluded owing to “insufficient EDSS follow-up” did not have a baseline visit with a recorded EDSS measurement within 6 months pre or 1-month post therapy commencement or had fewer than 2 post baseline visits 6 or more months apart.

#Patients excluded due to “inadequate visit frequency” did not have at least yearly visits with EDSS recorded during the treatment epoch. A treatment epoch was defined as time including three years prior to treatment start and one year (for the effect on relapses) and three years (for the effect on disability) after treatment start.

MS multiple sclerosis; RRMS remitting relapsing MS; CIS clinically isolated syndrome; DMT disease modifying therapy




Figure 2

Individual determinants of therapeutic lag for disability progression

EDSS: expanded disability status scale; ARR: annualised relapse rate

[= inclusive bracket

) = exclusive bracket




Figure 3

Interactions among the three determinants of therapeutic lag for disability progression (T_d)

- T_d was not calculated in groups of determinants with fewer than 300 progression events

EDSS: expanded disability status scale; ARR: annualised relapse rate; CI: confidence interval




Figure 4
Individual determinants of therapeutic lag for relapses

EDSS: expanded disability status scale; ARR: annualised relapse rate; RRMS: relapsing remitting MS; SPMS: secondary progressive MS
[: inclusive bracket;): exclusive bracket




Figure 5

Interactions among the three determinants of therapeutic lag for relapses

- T_r was not calculated in groups of determinants with fewer than 300 relapses or in which T_r was not identified in more than 80% of bootstrap replications.

EDSS: expanded disability status scale; SP: secondary progressive; RR: relapsing-remitting; ARR: annualised relapse rate; CI: confidence interval

